Stock Movers

Natalia Kinijevich, a Bloomberg News equities reporter specializing in market-moving companies, dives into recent stock developments. She discusses Novo Nordisk's major win with the U.S. approval of its oral Wegovy pill, setting up a competitive race against Eli Lilly. Natalia also analyzes ServiceNow's $7.75 billion acquisition of cybersecurity firm Armis, highlighting its significance for enterprise security. Finally, she covers the sharp 30% rise in Sable's shares following regulatory approval for a pipeline restart amid its challenging past.

Nora Melinda, a Bloomberg Television markets correspondent, shares her insights on major stock movements. Novo Nordisk celebrates its approval for an oral version of the obesity drug Wegovy, leading to a significant stock rally. On the downside, Johnson & Johnson faces a hefty $1.56 billion verdict related to talc litigation, impacting its shares. Meanwhile, ServiceNow announces its largest acquisition yet, buying cybersecurity startup Armis for $7.75 billion, though the market reacts cautiously.

Novo Nordisk celebrates after receiving US approval for a pill version of their obesity drug Wegovy, promising significant weight loss results. Meanwhile, Johnson & Johnson faces a staggering $1.56 billion verdict over its talc baby powder's alleged cancer links. In a bold move, ServiceNow announces a $7.75 billion acquisition of cybersecurity startup Armis, though its shares take a hit in response. Tune in for insights on these major market shifts!

Christine Aquino, a Bloomberg reporter and market analyst, dives into the fascinating developments in the stock world. Novo Nordisk makes headlines with its approval for an oral version of Wegovy, challenging Eli Lilly's dominance in the obesity market. Meanwhile, copper prices soar to record highs, boosting Albemarle's shares. Aquino also highlights the US Navy's ambitious plans for a new ship class, lifting Huntington Ingalls' stock. A thrilling discussion of market movements across pharmaceuticals, metals, and defense awaits!

Novo Nordisk's stock skyrocketed after gaining US approval for a pill version of its popular weight loss treatment, Wegovy, set to launch soon. Meanwhile, Huntington Ingalls saw its shares rally thanks to President Trump's announcement of a new battleship class, revitalizing the Navy's fleet amid budget concerns. In contrast, Orsted's stock dipped as the company considers legal action against the US decision to suspend offshore wind farm leases, raising issues about permits and national security.

Novo Nordisk's shares surged after approval for an oral obesity pill, challenging rival Eli Lilly. Huntington Ingalls' stock rose following President Trump's announcement of a new 'Trump-class' battleship. In the entertainment realm, Warner Bros. Discovery gained traction as Larry Ellison backed a competing bid against Netflix for the company, spurring a heated takeover battle.

Get ready for some intriguing business updates! Novo Nordisk secures U.S. approval for a Wegovy pill, shaking up the obesity treatment market. Meanwhile, Ryanair faces a hefty €256 million fine for allegedly hindering travel agencies, stirring the airline industry pot. Plus, Cevian Capital ups its stake in Akzo Nobel, putting pressure on the company to revamp its strategies. Dive into the economic implications of these shifts and what they mean for consumers and investors alike!

Louise Moon, a Bloomberg reporter specializing in market analysis, discusses significant market shifts. Novo Nordisk has secured US approval for a pill version of its weight-loss drug Wegovy, a strategic move against Eli Lilly. Orsted is facing challenges with the suspension of leases for five offshore wind farms, considering legal action amidst potential losses. Finally, Pets at Home has appointed James Bailey to revive its fortunes, aiming for a turnaround by 2026.

Shares of Warner Bros. Discovery surged as Larry Ellison personally backed Paramount's aggressive bid amidst a fierce takeover battle with Netflix. Meanwhile, First Solar's stock climbed after Alphabet's major acquisition of clean-energy company Intersect Power, highlighting the growing demand for AI-related data centers. Additionally, Clearwater Analytics made headlines with an $8.4 billion buyout, prompting discussions about the evolving landscape of tech investments and future market winners as firms navigate this competitive environment.

Warner Bros. Discovery sees its shares rise amid a fierce takeover rivalry, with Larry Ellison backing Paramount's bid against Netflix. In clean energy, First Solar jumps thanks to Alphabet's major acquisition of Intersect Power, promising benefits through 2029. Navan's shares soar after its inclusion in significant Russell indexes, despite a slump since its IPO. Discussions also highlight analyst optimism for Navan's future, coupled with predictions for a new wave of IPOs across different sectors.